New antithrombotic 1-Phthalazinamines with Serotonin Antagonistic Properties

Archiv der Pharmazie

Volumn 336, Issue 12, 2003, Pages 591-597

  Johnsen, Matthias ^a   Rehse, Klaus ^a   Pertz, Heinz ^a   Stasch, Johannes Peter ^b   Bischoff, Erwin ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BAYER AG   (Germany)

Author keywords

1 Phthalazinamine; Antithrombotic properties; Born test; Laser thrombosis model; Serotonin antagonism

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1 PHTHALAZINAMINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; N (FURAN 2 YLMETHYL) 4 PHENYL 1 PHTHALAZINAMINE; N [4 (1H 1,2,4 TRIAZOL 1 YL)BUTYL] 4 PHENYL 1 PHTHALAZINAMINE; N [5 (1H 1,2,4 TRIAZOL 1 YL)PENTYL] 4 PHENYL 1 PHTHALAZINAMINE; SEROTONIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SEROTONINERGIC TRANSMISSION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; COLLAGEN; DRUG DESIGN; FIBRINOLYTIC AGENTS; GUANYLATE CYCLASE; HUMANS; LASERS; MALE; PHOSPHODIESTERASE INHIBITORS; PHTHALAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 0345763017     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.200300775     Document Type: Article

References (12)

1. F.-N. Ko, C.-C. Wu, S. C. Kuo, F. Y. Lee, C. M. Teng, Blood 1994, 84, 4226-4233.
2. J. Galle et al., Br. J. Pharmacol. 1999, 127, 195-203.
3. H. M. Holava Jr., R. A. Partyka, J. Med. Chem. 1969, 12, 555-557.
4. S. Gabriel, A. Michael, Ber. 1878, 11, 1007-1021.
5. F. Seuter, Haemostasis 1976, 5, 85-95.
6. G. V. R. Born, Nature (London) 1962, 194, 927-929.
7. K. Rehse, T. Ciborski, V. Schein, M. Kämpfe, B. Rose, E. Unsöld, Arch. Pharm. 1991, 324, 301-305.
8. K. Rehse, T. Ciborski, Arch. Pharm. 1995, 328, 71-75.
9. I. Saenz de Tejada, J. Anguo, P. Cuevas, A. Fernández, I. Moncada, A. Allona, E. Lledó, H. G. Körschen, U. Niewöhner, H. Haning, E. Pages, E. Bischoff, Int. J. Impot. Res. 2001, 13, 282-290.
10. M. Hoenika, E.-M. Becker, H. Apeler, T. Sirichoke, H. Schröder, R. Gerzer, J.-P. Stasch, J. Mol. Med. 1999, 77, 14-23.
11. H. Pertz, S. Elz, J. Pharm. Pharmacol. 1995, 47, 310-316.
12. R. F. Furchgott, In: Blaschko, H., Muscholl, E. (Eds.) Catecholamines, Handbook of Experimental Pharmacology 33,. Springer Verlag, Berlin 1972, S. 283-335.